NCT02772198

A Phase 1 / 2 Single Arm Study of T-cells Expressing Anti-CD19 Chimeric Antigen Receptor in Pediatric and Young Adult Patients With B-cell Malignancies

Study Summary

This phase 1 / 2 study will evaluate the response of B-cell malignancies expressing CD19 to autologous T cells transduced with a second generation anti-CD19 chimeric antigen receptor in children and young adults.

Interested in this trial?

Submit an Inquiry

Interventions

CD19 CAR T cellsBIOLOGICAL

Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19

Study Locations

Facility	City	State	Country
Chaim Sheba Medical Center	Ramat Gan		Israel

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026